NMPA Deputy Commissioner Yang Sheng Visits LBE Pharma for Inspection and Guidance, Supporting the Company's Innovation-Driven Development

On June 17, 2026, Mr. Yang Sheng, Member of the Party Leadership Group and Deputy Commissioner of the National Medical Products Administration (NMPA), led a delegation to LBE Pharma for an inspection and guidance visit. The visit aimed to gain an in-depth understanding of the company's business operations, technological innovation, product registration, and overall production and operations. The delegation listened to the company's development needs on-site, offering valuable guidance and support for the company's continued innovation-driven growth.

Accompanying Deputy Commissioner Yang were Ms. He Li, Director-General of the Department of Science, Technology and International Cooperation; Mr. Lan Gongtao, Deputy Director-General of the Department of Drug Registration; and relevant section heads. The visit was also accompanied by Mr. Huang Weijun, Director of the Fujian Medical Products Administration, along with relevant department heads, and leaders from the Fuzhou New Area. The company was represented by Dr. Tseng Weihong, Executive Vice President, and Dr. Lu Yang, Assistant to the President and R&D Director, who warmly received the delegation and provided detailed briefings on the company's various activities.

Part 01: Understanding the Company's Development Needs and Innovation Strategy

During the investigation, Deputy Commissioner Yang and his team listened to the company's needs and gained a full picture of its development history and strategic positioning. Dr. Tseng provided a comprehensive overview of the company's development milestones, medium- and long-term strategic plans, achievements in establishing its core technology platforms, and the development progress and commercialization plans for its proprietary pipeline products. Live demonstrations were also conducted on-site, intuitively showcasing the technical advantages, functional features, and application value of the company's products, allowing the delegation to gain a comprehensive understanding of LBE Pharma's innovative R&D outcomes and industrialization capabilities.

Part 02: Supporting the Translation of Innovative Achievements into Commercial Success

During the inspection, the delegation carefully listened to the briefings and observed product demonstrations in detail. They inquired deeply into the difficulties and needs faced by the company in R&D innovation, product registration, market promotion, and future growth. In response, and in consideration of pharmaceutical regulatory policies and industry trends, they provided on-the-spot guidance and clarification, offering strong support for the the efficient commercialization of the company's innovative products and technologies.

Part 03: Expressing High Expectations for Greater Cross-Strait Industrial Collaboration

Deputy Commissioner Yang spoke highly of the company's development results, innovative capabilities, and commitment to compliance. He noted that LBE Pharma, by deepening its focus in specialized pharmaceutical segments and focusing on the development of high-end pharmaceutical formulations and drug-device combination products, has established a robust technology development and quality management system—an important contributor to ensuring medication safety and strengthening emergency healthcare preparedness. The company's products feature prominent innovations and a solid industrialization foundation. By fully leveraging the favorable conditions for cross-strait integration, LBE Pharma has deepened industrial collaboration between Fujian and Taiwan, as well as across the strait, serving as a model for cross-strait collaboration in the pharmaceutical industry.

Part 04: Implementing the Guidance and Advancing Innovation-Driven Development

The company will thoroughly implement the guiding principles from this visit, seizing opportunities in the innovation-driven development of the pharmaceutical industry. With the support and guidance of the NMPA, LBE Pharma will continue to deepen technological innovation, rigorously uphold quality standards, and enhance its product development capabilities. At the same time, the company will actively serve as a bridge to promote the exchange of pharmaceutical industry resources between Fujian and Taiwan, contribute to the high-quality development of the cross-strait healthcare industry.